aspirin + clopidogrel + cilostazol (Xuanwu Hospital)

This entry refers to an individualized antithrombotic treatment regimen guided by Thromboelastography (TEG) for the secondary prevention of ischemic stroke and cerebrovascular disease. Developed and studied at Xuanwu Hospital in Beijing, the protocol involves monitoring platelet reactivity using TEG to adjust the selection and dosage of antiplatelet agents, specifically aspirin, clopidogrel, and cilostazol. The goal is to achieve 'desirable' TEG parameters to optimize therapeutic efficacy and minimize the risk of recurrent stroke or bleeding complications. The regimen typically involves switching between or combining these small molecule inhibitors based on the patient's specific coagulation profile as measured by the TEG device.

Brand names

Bayaspirin

Other names

Individualized Antithrombotic Therapy guided by TEGDesirable TEGUndesirable TEG